Company News: Dendreon

Share this article:
Dendreon's Provenge prostate cancer vaccine, the first in a new class of cancer treatments that use the patient's own immune system, received FDA approval. The vaccine, approved for men with the advanced form of the disease, is designed to induce an immune response against prostatic acid phosphatase, an antigen expressed in most prostate cancers. Provenge (sipuleucel-T) belongs to a new therapeutic class called autologous cellular immunotherapies and could usher in an entirely new treatment paradigm for patients with cancer. Several other companies are developing immunotherapies targeting tumor antigens.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Janssen recruits Debbie Allen for T2 Diabetes

Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.

Pfizer seeks wider Xeljanz indication

The company expects to file an sNDA for plaque psoriasis next year.

Recalls dent Stryker Q1 earnings

Sales rose 5% compared to the same period last year.